What Will Drive Korean Pharma's Next Decade Of Growth?
Ample Pipelines, Direct Global Entry May Be Key
A recent event in South Korea heard one prominent investor advise South Korean pharma firms to sharply increase their new drug R&D and seek direct entry into global markets, rather than pursuing licensing deals for growth
You may also be interested in...
Korea's Samsung Biologics talked during the BIO Digital event about the key trends and new paradigms in the CDMO industry in the COVID-19 era, including expansion, diversification and personalization. Forward planning helped overcome pandemic-related challenges but logistics remains a major challenge.
PharmaVentures’ Adrian Dawkes talks about how COVID-19 will impact pharma deals going forward and how Korean firms in particular may be able to grab opportunities in the global arena.
The Bio Korea meeting included a discussion around the challenges faced by Korean developers of COVID-19 therapies and vaccines and how they should approach the global market. Cooperation and production technology will be key.